12/6
06:02 am
ikt
Form EFFECT Inhibikase Therapeutics,
High
Report
Form EFFECT Inhibikase Therapeutics,
12/5
04:51 pm
ikt
Form 8-K Inhibikase Therapeutics, For: Dec 02
High
Report
Form 8-K Inhibikase Therapeutics, For: Dec 02
12/5
04:48 pm
ikt
Form 424B3 Inhibikase Therapeutics,
High
Report
Form 424B3 Inhibikase Therapeutics,
12/3
06:25 am
ikt
Form S-3/A Inhibikase Therapeutics,
Medium
Report
Form S-3/A Inhibikase Therapeutics,
11/18
04:49 pm
ikt
Form S-3 Inhibikase Therapeutics,
Low
Report
Form S-3 Inhibikase Therapeutics,
11/18
04:05 pm
ikt
Form DEF 14A Inhibikase Therapeutics, For: Jan 03
Low
Report
Form DEF 14A Inhibikase Therapeutics, For: Jan 03
11/14
03:31 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G Inhibikase Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
11/14
08:31 am
ikt
Form 10-Q Inhibikase Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Inhibikase Therapeutics, For: Sep 30
11/8
04:10 pm
ikt
Form PRE 14A Inhibikase Therapeutics, For: Jan 03
High
Report
Form PRE 14A Inhibikase Therapeutics, For: Jan 03
10/28
05:27 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: SP IKT Holdings LLC
Low
Report
Form SC 13G Inhibikase Therapeutics, Filed by: SP IKT Holdings LLC
10/28
04:01 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: Soleus Private Equity Fund III, L.P.
Medium
Report
Form SC 13G Inhibikase Therapeutics, Filed by: Soleus Private Equity Fund III, L.P.
10/25
05:53 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
High
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
10/25
05:51 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
High
Report
Form SC 13G Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
10/23
07:58 pm
ikt
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Canner David
Low
Report
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Canner David
10/23
07:54 pm
ikt
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Bellini Roberto
Low
Report
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Bellini Roberto
10/23
07:50 pm
ikt
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Kush Arvind
Low
Report
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Kush Arvind
10/23
07:44 pm
ikt
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Munshi Amit
Low
Report
Form 4 Inhibikase Therapeutics, For: Oct 21 Filed by: Munshi Amit
10/23
07:41 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Kush Arvind
Low
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Kush Arvind
10/23
07:39 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Canner David
Low
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Canner David
10/23
07:36 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Bellini Roberto
Low
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Bellini Roberto
10/23
07:36 pm
ikt
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Munshi Amit
Low
Report
Form 3 Inhibikase Therapeutics, For: Oct 21 Filed by: Munshi Amit
10/22
04:16 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
High
Report
Form SC 13G Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
10/22
06:01 am
ikt
Form 8-K Inhibikase Therapeutics, For: Oct 21
Medium
Report
Form 8-K Inhibikase Therapeutics, For: Oct 21
10/17
07:01 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: Fairmount Funds Management LLC
High
Report
Form SC 13G Inhibikase Therapeutics, Filed by: Fairmount Funds Management LLC
10/17
04:05 pm
ikt
Form SC 13G Inhibikase Therapeutics, Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SC 13G Inhibikase Therapeutics, Filed by: COMMODORE CAPITAL LP